Mitchell S. Kapoor
Stock Analyst at HC Wainwright & Co.
(4.48)
# 297
Out of 5,238 analysts
105
Total ratings
56.84%
Success rate
20.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mitchell S. Kapoor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Maintains: Buy | $16 → $25 | $13.66 | +83.02% | 2 | May 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Neutral | $55 | $54.06 | +1.74% | 6 | May 5, 2026 | |
| INCY Incyte | Reiterates: Buy | $135 | $98.56 | +36.97% | 7 | May 4, 2026 | |
| SMMT Summit Therapeutics | Maintains: Buy | $30 → $23 | $18.08 | +27.21% | 9 | May 4, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $120 → $125 | $75.71 | +65.10% | 8 | Apr 30, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $75 → $120 | $64.59 | +85.79% | 4 | Apr 29, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $90 → $95 | $64.12 | +48.16% | 6 | Apr 29, 2026 | |
| KYTX Kyverna Therapeutics | Reiterates: Buy | $20 | $9.35 | +113.90% | 3 | Apr 23, 2026 | |
| IPSC Century Therapeutics | Maintains: Buy | $2 → $5 | $2.29 | +118.34% | 1 | Apr 21, 2026 | |
| LEGN Legend Biotech | Reiterates: Buy | $50 | $28.12 | +77.81% | 4 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sell | $5 | $19.96 | -74.94% | 5 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $25 | $23.66 | +5.66% | 4 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.80 | +288.89% | 1 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $40 | $21.57 | +85.44% | 3 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $50 | $22.92 | +118.15% | 3 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $17 | $3.98 | +327.14% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $14.09 | +112.92% | 7 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $22 | $18.76 | +17.27% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $45 | $34.32 | +31.12% | 2 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $12.05 | +65.98% | 3 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $30.78 | +127.42% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $5.83 | +71.53% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.16 | - | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 → $45 | $19.33 | +132.80% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.82 | +103.67% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $30 | $8.65 | +246.82% | 1 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $54.83 | +45.91% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.11 | +60.77% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.41 | +396.45% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $4.79 | -58.25% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.44 | +177.78% | 1 | Aug 11, 2025 |
Generate Biomedicines
May 8, 2026
Maintains: Buy
Price Target: $16 → $25
Current: $13.66
Upside: +83.02%
BioMarin Pharmaceutical
May 5, 2026
Reiterates: Neutral
Price Target: $55
Current: $54.06
Upside: +1.74%
Incyte
May 4, 2026
Reiterates: Buy
Price Target: $135
Current: $98.56
Upside: +36.97%
Summit Therapeutics
May 4, 2026
Maintains: Buy
Price Target: $30 → $23
Current: $18.08
Upside: +27.21%
Ionis Pharmaceuticals
Apr 30, 2026
Maintains: Buy
Price Target: $120 → $125
Current: $75.71
Upside: +65.10%
Oruka Therapeutics
Apr 29, 2026
Maintains: Buy
Price Target: $75 → $120
Current: $64.59
Upside: +85.79%
Halozyme Therapeutics
Apr 29, 2026
Maintains: Buy
Price Target: $90 → $95
Current: $64.12
Upside: +48.16%
Kyverna Therapeutics
Apr 23, 2026
Reiterates: Buy
Price Target: $20
Current: $9.35
Upside: +113.90%
Century Therapeutics
Apr 21, 2026
Maintains: Buy
Price Target: $2 → $5
Current: $2.29
Upside: +118.34%
Legend Biotech
Apr 21, 2026
Reiterates: Buy
Price Target: $50
Current: $28.12
Upside: +77.81%
Apr 16, 2026
Reiterates: Sell
Price Target: $5
Current: $19.96
Upside: -74.94%
Mar 30, 2026
Maintains: Buy
Price Target: $40 → $25
Current: $23.66
Upside: +5.66%
Mar 26, 2026
Initiates: Buy
Price Target: $7
Current: $1.80
Upside: +288.89%
Mar 25, 2026
Maintains: Buy
Price Target: $25 → $40
Current: $21.57
Upside: +85.44%
Mar 18, 2026
Maintains: Buy
Price Target: $65 → $50
Current: $22.92
Upside: +118.15%
Mar 16, 2026
Maintains: Buy
Price Target: $10 → $17
Current: $3.98
Upside: +327.14%
Mar 3, 2026
Maintains: Buy
Price Target: $25 → $30
Current: $14.09
Upside: +112.92%
Mar 2, 2026
Maintains: Buy
Price Target: $25 → $22
Current: $18.76
Upside: +17.27%
Feb 17, 2026
Maintains: Buy
Price Target: $30 → $45
Current: $34.32
Upside: +31.12%
Jan 29, 2026
Upgrades: Buy
Price Target: $20
Current: $12.05
Upside: +65.98%
Jan 13, 2026
Reiterates: Buy
Price Target: $70
Current: $30.78
Upside: +127.42%
Jan 13, 2026
Maintains: Buy
Price Target: $13 → $10
Current: $5.83
Upside: +71.53%
Jan 7, 2026
Downgrades: Neutral
Price Target: n/a
Current: $8.16
Upside: -
Dec 9, 2025
Upgrades: Buy
Price Target: $20 → $45
Current: $19.33
Upside: +132.80%
Nov 24, 2025
Initiates: Buy
Price Target: $20
Current: $9.82
Upside: +103.67%
Nov 19, 2025
Maintains: Buy
Price Target: $40 → $30
Current: $8.65
Upside: +246.82%
Sep 23, 2025
Reiterates: Buy
Price Target: $80
Current: $54.83
Upside: +45.91%
Sep 5, 2025
Reiterates: Buy
Price Target: $5
Current: $3.11
Upside: +60.77%
Aug 19, 2025
Reiterates: Buy
Price Target: $7
Current: $1.41
Upside: +396.45%
Aug 19, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $4.79
Upside: -58.25%
Aug 11, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.44
Upside: +177.78%